stockrowEli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Eli Lilly and Company (LLY) Current ratio
Eli Lilly and Company's current ratio at the end of the quarter to 30 September 2026 was 1.4×, down 0.2× from fiscal 2025 (1.6×). Over the past ten years it has ranged from 0.9× (fiscal 2023) to 1.7× (fiscal 2018); the current reading is higher than 91% of that period. That is in line with the Drug Manufacturers General industry median of 1.4× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.6× | 36.86% |
| FY2024 | 1.2× | 22.41% |
| FY2023 | 0.9× | (10.42%) |
| FY2022 | 1.1× | (14.16%) |
| FY2021 | 1.2× | (12.37%) |
| FY2020 | 1.4× | 20.16% |
| FY2019 | 1.2× | (32.64%) |
| FY2018 | 1.7× | 30.86% |
| FY2017 | 1.3× | (3.89%) |
| FY2016 | 1.4× | (10.04%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 1.4× | 2.52% |
| Jun 2026 | 1.4× | (9.50%) |
| Mar 2026 | 1.5× | (5.21%) |
| Dec 2025 | 1.6× | 2.12% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| AMGN Amgen Inc. compare | 1.5× |
| PFE Pfizer Inc. compare | 1.4× |
| LLY Eli Lilly and Company | 1.4× |
| GILD Gilead Sciences, Inc. compare | 1.4× |
| MRK Merck & Co., Inc. compare | 1.3× |
| JNJ Johnson & Johnson compare | 1.0× |
| AZN AstraZeneca PLC compare | 1.0× |
| NVS Novartis AG compare | 0.9× |
| ABBV AbbVie Inc. compare | 0.9× |
| Drug Manufacturers General industry median | 1.4× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on LLY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement